

# Brendan Frett

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8344326/publications.pdf>

Version: 2024-02-01

46  
papers

989  
citations

393982

19  
h-index

454577

30  
g-index

57  
all docs

57  
docs citations

57  
times ranked

1561  
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 1536-1551.	2.9	4
2	Targeting TGF $\beta$ 2: triumphs and challenges. <i>Future Medicinal Chemistry</i> , 2022, , .	1.1	1
3	FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms. <i>RSC Medicinal Chemistry</i> , 2022, 13, 798-816.	1.7	7
4	Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach. <i>ChemMedChem</i> , 2021, 16, 1605-1608.	1.6	3
5	Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2021, 216, 113265.	2.6	21
6	Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases. <i>Scientific Reports</i> , 2021, 11, 16103.	1.6	5
7	Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 11747-11773.	2.9	13
8	Discovery and biological evaluation of phthalazines as novel non-kinase TGF $\beta$ 2 pathway inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2021, 223, 113660.	2.6	2
9	Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor. <i>European Journal of Medicinal Chemistry</i> , 2021, 225, 113776.	2.6	8
10	Discovery of 4-aminoquinolines as highly selective TGF $\beta$ 2R1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology. <i>European Journal of Medicinal Chemistry</i> , 2021, 225, 113763.	2.6	1
11	The Exploration of Chirality for Improved Druggability within the Human Kinome. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 441-469.	2.9	27
12	One-pot construction of functionalized aziridines and maleimides via a novel pseudo-Knoevenagel cascade reaction. <i>Chemical Communications</i> , 2020, 56, 2194-2197.	2.2	8
13	Structural Characterization of the Aurora Kinase B $\alpha$ -DFG-flip-Using Metadynamics. <i>AAPS Journal</i> , 2020, 22, 14.	2.2	13
14	Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression. <i>European Journal of Medicinal Chemistry</i> , 2020, 203, 112589.	2.6	21
15	Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2020, 206, 112691.	2.6	16
16	ProteoViz: a tool for the analysis and interactive visualization of phosphoproteomics data. <i>Molecular Omics</i> , 2020, 16, 316-326.	1.4	19
17	Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4506-4516.	2.9	20
18	Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2. <i>Journal of Clinical Investigation</i> , 2020, 130, 5027-5027.	3.9	0

#	ARTICLE	IF	CITATIONS
19	Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2. <i>Journal of Clinical Investigation</i> , 2020, 130, 6187-6187.	3.9	7
20	Intramolecular cyclization of imidazo[1,2- <i>a</i> ]pyridines via a silver mediated/palladium catalyzed C-H activation strategy. <i>Organic Chemistry Frontiers</i> , 2019, 6, 2234-2239.	2.3	12
21	Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1731-1760.	2.9	58
22	Use of Imidazo[1,2- <i>a</i> ]pyridine as a Carbonyl Surrogate in a Mannich-Like, Catalyst Free, One-Pot Reaction. <i>European Journal of Organic Chemistry</i> , 2019, 2019, 770-777.	1.2	17
23	Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT. <i>Scientific Reports</i> , 2018, 8, 3722.	1.6	13
24	Recent advances in the development of polycyclic skeletons via Ugi reaction cascades. <i>Molecular Diversity</i> , 2018, 22, 503-516.	2.1	28
25	Catalyst free, C-3 functionalization of imidazo[1,2- <i>a</i> ]pyridines to rapidly access new chemical space for drug discovery efforts. <i>Chemical Communications</i> , 2018, 54, 12954-12957.	2.2	31
26	Diversity-Oriented Synthesis of Functionalized Imidazopyridine Analogues with Anti-Cancer Activity through a Transition-Metal Free, One-Pot Cascade Reaction. <i>Advanced Synthesis and Catalysis</i> , 2018, 360, 3655-3661.	2.1	10
27	Selective, C-3 Friedel-Crafts acylation to generate functionally diverse, acetylated Imidazo[1,2- <i>a</i> ]pyridine derivatives. <i>Tetrahedron</i> , 2018, 74, 4592-4600.	1.0	13
28	Facile construction of fused benzimidazole-isoquinolinones that induce cell-cycle arrest and apoptosis in colorectal cancer cells. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 3899-3908.	1.4	24
29	Structure-based design and synthesis of imidazo[1,2- <i>a</i> ]pyridine derivatives as novel and potent Nek2 inhibitors with <i>in vitro</i> and <i>in vivo</i> antitumor activities. <i>European Journal of Medicinal Chemistry</i> , 2017, 126, 1083-1106.	2.6	41
30	Synthesis of Constrained Heterocycles Employing Two Post-Ugi Cyclization Methods for Rapid Library Generation with <i>In Cellulo</i> Activity. <i>ChemistrySelect</i> , 2017, 2, 11821-11825.	0.7	1
31	Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2. <i>Journal of Clinical Investigation</i> , 2017, 127, 3075-3089.	3.9	86
32	Preclinical activity of MBM-5 in gastrointestinal cancer by inhibiting NEK2 kinase activity. <i>Oncotarget</i> , 2016, 7, 79327-79341.	0.8	11
33	Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology. <i>Angewandte Chemie - International Edition</i> , 2015, 54, 8717-8721.	7.2	33
34	Metal-free, efficient hydrazination of imidazo[1,2- <i>a</i> ]pyridine with diethyl azodicarboxylate in neutral media. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 2958-2964.	1.5	36
35	Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2015, 94, 123-131.	2.6	22
36	An expeditious approach to access 2-arylimidazo[1,2- <i>a</i> ]pyridin-3-ol from 2-amino pyridine through a novel Petasis based cascade reaction. <i>Tetrahedron Letters</i> , 2014, 55, 1281-1284.	0.7	18

#	ARTICLE	IF	CITATIONS
37	Efficient Access to 2,3-Diarylimidazo[1,2- <i>a</i> ]pyridines via a One-Pot, Ligand-Free, Palladium-Catalyzed Three-Component Reaction under Microwave Irradiation. <i>Organic Letters</i> , 2014, 16, 3016-3019.	2.4	51
38	Identification of pyrazine-based TrkA inhibitors: design, synthesis, evaluation, and computational modeling studies. <i>MedChemComm</i> , 2014, 5, 1507-1514.	3.5	9
39	Identification of two novel RET kinase inhibitors through MCR-based drug discovery: Design, synthesis and evaluation. <i>European Journal of Medicinal Chemistry</i> , 2014, 86, 714-723.	2.6	20
40	Therapeutic Melting Pot of Never in Mitosis Gene A Related Kinase 2 (Nek2): A Perspective on Nek2 as an Oncology Target and Recent Advancements in Nek2 Small Molecule Inhibition. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 5835-5844.	2.9	21
41	Selective Reduction of Halogenated Nitroarenes with Hydrazine Hydrate in the Presence of Pd/C. <i>Synlett</i> , 2014, 25, 1403-1408.	1.0	55
42	Targeting the Ras/PDE4 Protein-Protein Interaction: The Solution for Ras-Driven Cancers or Just Another Therapeutic Mirage?. <i>ChemMedChem</i> , 2013, 8, 1620-1622.	1.6	2
43	A <i>p</i> -toluenesulfinic acid-catalyzed three-component Ugi-type reaction and its application for the synthesis of $\alpha$ -amino amides and amidines. <i>Tetrahedron Letters</i> , 2013, 54, 2340-2343.	0.7	30
44	Targeting Mutant KRAS for Anticancer Therapeutics: A Review of Novel Small Molecule Modulators. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 5219-5230.	2.9	104
45	( <i>Z</i> )- <i>N</i> - <i>tert</i> -Butyl-2-(4-methoxyanilino)- <i>N</i> -(4-methoxyphenyl)-2-phenylacetimidamide. <i>Acta Crystallographica Section E: Structure Reports Online</i> , 2013, 69, o902-o902.	0.2	0
46	Synthesis of tetrazolo-fused benzodiazepines and benzodiazepinones by a two-step protocol using an Ugi-azide reaction for initial diversity generation. <i>Tetrahedron</i> , 2012, 68, 5606-5611.	1.0	41